Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lymphodepleting Chemotherapy”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Testing effectiveness (Phase 2)Study completedNCT01181258
What this trial is testing

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Who this might be right for
Non-Hodgkin LymphomaChronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota 16
Testing effectiveness (Phase 2)Study completedNCT00923195
What this trial is testing

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Who this might be right for
MelanomaSkin Cancer
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Looking for participantsNCT05909059
What this trial is testing

CAR T-cell Therapy in Patients With Renal Dysfunction

Who this might be right for
Non-hodgkin Lymphoma,B CellMultiple MyelomaAcute Lymphoblastic Leukemia, Adult
Northside Hospital, Inc. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06434363
What this trial is testing

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Who this might be right for
Autoimmune DisordersSystemic SclerosisSystemic Lupus Erythematosus+2 more
M.D. Anderson Cancer Center 47
Early research (Phase 1)Study completedNCT01875601
What this trial is testing

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Who this might be right for
Solid TumorsBrain TumorsSarcoma+2 more
National Cancer Institute (NCI) 16
Early research (Phase 1)Active Not RecruitingNCT07209241
What this trial is testing

Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Who this might be right for
Recurrent Glioblastoma
University of Pennsylvania 12
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Testing effectiveness (Phase 2)Temporarily pausedNCT05703854
What this trial is testing

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Who this might be right for
Advanced Renal Cell CarcinomaAdvanced MesotheliomaAdvanced Osteosarcoma
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105021
What this trial is testing

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Who this might be right for
Pancreatic Ductal AdenocarcinomaNon-Small Cell Lung CancerColorectal Cancer+2 more
Affini-T Therapeutics, Inc. 100
Early research (Phase 1)Active Not RecruitingNCT02146924
What this trial is testing

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
City of Hope Medical Center 71
Early research (Phase 1)WithdrawnNCT06572631
What this trial is testing

Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid Leukemia+1 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT00670748
What this trial is testing

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Who this might be right for
Metastatic MelanomaMetastatic Renal Cell CancerMetastatic Cancer
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT03610724
What this trial is testing

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Who this might be right for
Non-Hodgkin Lymphoma
Novartis Pharmaceuticals 34
Early research (Phase 1)Temporarily pausedNCT06447987
What this trial is testing

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
City of Hope Medical Center 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07137481
What this trial is testing

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

Who this might be right for
Hematological Malignancies
M.D. Anderson Cancer Center 70
Testing effectiveness (Phase 2)Ended earlyNCT00303836
What this trial is testing

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Who this might be right for
Recurrent MelanomaStage IV Melanoma
National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)Looking for participantsNCT05110742
What this trial is testing

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Who this might be right for
Hematological Malignancy
M.D. Anderson Cancer Center 64
Early research (Phase 1)Active Not RecruitingNCT02153580
What this trial is testing

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Who this might be right for
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaB-Cell Prolymphocytic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise Specified+10 more
City of Hope Medical Center
Early research (Phase 1)Study completedNCT02280525
What this trial is testing

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Looking for participantsNCT06930651
What this trial is testing

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Who this might be right for
Myeloid Malignancies
M.D. Anderson Cancer Center 42
Next Page
37